anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

All filtered slides

Global slide inventory for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Corpus coverage

319,975 slides

319,974 are described (100%), so the treemap can explain the corpus instead of just counting files.

Total slides
319,975
Described
319,974
Pending
1

Slide type composition

dynamicclickable
Slide type

Showing 319,974 described slides — 100.0% of 319,975 rendered pages

+Context & problem43,76713.7% · 6,592 docs+Data & charts72,62022.7% · 8,666 docs+Meta & navigation45,93614.4% · 9,739 docs+Recommend & act67,04121.0% · 9,324 docs+Cases & evidence31,2569.8% · 6,067 docs+Frameworks2,1230.7% · 1,232 docs+Appendix35,68211.2% · 6,614 docs+Other21,5496.7% · 5,566 docs

Tile area is proportional to slide count. Click a category to open its subtype map.

all document kinds · all orientations
18 30 60

Slide collection

230,701-230,760 of 319,975

filter-aware
40
The slide uses a four-column layout with upward-pointing arrows to signify growth/improvement.Hugo Boss | Results Presentation Deck | 44 slides · Hugo Boss
Conference presentation Investor relations Beat · Action1 hit
41
The slide uses a split-screen layout with key drivers on the left and a bar chart on the right.Hugo Boss | Results Presentation Deck | 44 slides · Hugo Boss
Conference presentation Investor relations Beat · Action1 hit
42
This is a transition or summary slide, likely setting the stage for the operational and financial sections of the presentation.Hugo Boss | Results Presentation Deck | 44 slides · Hugo Boss
Conference presentation Investor relations Beat · Action1 hit
43
Hugo Boss | Results Presentation Deck | 44 slidesHugo Boss | Results Presentation Deck | 44 slides · Hugo Boss
Conference presentation Investor relations Beat · Action1 hit
44
Hugo Boss | Results Presentation Deck | 44 slidesHugo Boss | Results Presentation Deck | 44 slides · Hugo Boss
Conference presentation Investor relations Beat · Action1 hit
01
Slide 1
Immix Biopharma | Investor Presentation Deck | 56 slidesImmix Biopharma | Investor Presentation Deck | 56 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
02
Immix Biopharma | Investor Presentation Deck | 56 slidesImmix Biopharma | Investor Presentation Deck | 56 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
03
The slide uses a three-column layout for strategic pillars followed by a bottom section highlighting clinical performance metrics.Immix Biopharma | Investor Presentation Deck | 56 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
04
The slide uses a grid-based layout to categorize team members into three distinct organizational tiers.Immix Biopharma | Investor Presentation Deck | 56 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
05
The slide uses a Gantt-style chart to represent clinical trial stages.Immix Biopharma | Investor Presentation Deck | 56 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
06
The slide uses a visual arrow graphic to imply forward momentum.Immix Biopharma | Investor Presentation Deck | 56 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
07
The slide uses a structural diagram to map technical modifications to clinical outcomes.Immix Biopharma | Investor Presentation Deck | 56 slides · Immix Biopharma
Pitch deck Investor relations Beat · Solution1 hit
08
The slide uses a comparison framework to contrast standard industry benchmarks with the company's clinical data.Immix Biopharma | Investor Presentation Deck | 56 slides · Immix Biopharma
Pitch deck Investor relations Beat · Solution1 hit
09
The slide uses a process flow diagram to connect cellular pathology to clinical organ damage.Immix Biopharma | Investor Presentation Deck | 56 slides · Immix Biopharma
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
10
Includes a biological pathway diagram showing B-cell maturation and a pyramid diagram showing the hierarchy of disease targeting.Immix Biopharma | Investor Presentation Deck | 56 slides · Immix Biopharma
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
11
Includes a biological process diagram showing the interaction between NXC-201 CAR-T cells and disease-causing LLPC clones.Immix Biopharma | Investor Presentation Deck | 56 slides · Immix Biopharma
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
12
Includes dot plot for BCMA expression, bar chart for IFNy activation, and flow cytometry plots showing cell elimination.Immix Biopharma | Investor Presentation Deck | 56 slides · Immix Biopharma
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
13
Uses a bar chart to compare CRS duration in days across four competitors, with NXC-201 highlighted as significantly lower.Immix Biopharma | Investor Presentation Deck | 56 slides · Immix Biopharma
Pitch deck Investor relations Beat · AgitateLoop · Cost Of Inaction1 hit
14
The slide uses a bar chart to compare neurotoxicity percentages and a table to compare clinical metrics like CRS onset and duration.Immix Biopharma | Investor Presentation Deck | 56 slides · Immix Biopharma
Pitch deck Investor relations Beat · AgitateLoop · Cost Of Inaction1 hit
15
The slide highlights NXC-201's 100% overall response rate and superior cardiac response compared to CAEL-101 and Birtamimab.Immix Biopharma | Investor Presentation Deck | 56 slides · Immix Biopharma
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
16
The chart is a swimmer plot showing patient response duration, with an annotation indicating the target population for future enrollment.Immix Biopharma | Investor Presentation Deck | 56 slides · Immix Biopharma
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
17
The slide uses a visual comparison between existing standard-of-care treatments (left) and the NXC-201 opportunity (center/right).Immix Biopharma | Investor Presentation Deck | 56 slides · Immix Biopharma
Pitch deck Investor relations Beat · Market SizeLoop · Quick Win Big Bet1 hit
18
N-GENIUS TECHNOLOGY PLATFORM; NEXICART-1 Clinical Trial Data.Immix Biopharma | Investor Presentation Deck | 56 slides · Immix Biopharma
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
19
Includes comparative data points for transduction efficiency and experimental data for tonic signaling and exhaustion.Immix Biopharma | Investor Presentation Deck | 56 slides · Immix Biopharma
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
20
Includes citations from Nature Medicine and Signal Transduction and Targeted Therapy to validate the scientific approach.Immix Biopharma | Investor Presentation Deck | 56 slides · Immix Biopharma
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
21
Uses a combination of bar charts for preclinical data and a comparison table for clinical outcomes to demonstrate the superiority of the CD8 hinge optimization.Immix Biopharma | Investor Presentation Deck | 56 slides · Immix Biopharma
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
22
The slide uses a schematic to compare HSL and LSH configurations, showing superior performance for HSL in expansion and cytotoxicity metrics.Immix Biopharma | Investor Presentation Deck | 56 slides · Immix Biopharma
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
23
Includes a footnote citing FDA approval precedents for single-arm studies.Immix Biopharma | Investor Presentation Deck | 56 slides · Immix Biopharma
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
24
Immix Biopharma | Investor Presentation Deck | 56 slidesImmix Biopharma | Investor Presentation Deck | 56 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
25
The slide uses a comparative diagram to show structural differences between NXC-201 and Abecma.Immix Biopharma | Investor Presentation Deck | 56 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
26
The diagram shows a summation of two patient groups (prevalence and incidence-derived relapsed/refractory) to reach a total eligible patient count.Immix Biopharma | Investor Presentation Deck | 56 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
27
The slide uses a molecular biology diagram to illustrate structural differences in binding domains and intracellular signaling components.Immix Biopharma | Investor Presentation Deck | 56 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
28
The slide uses a visual comparison of three treatment timelines to highlight the superior safety profile of NXC-201.Immix Biopharma | Investor Presentation Deck | 56 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
29
The table compares NXC-201 against Darzalex, CAEL-101, and Birtamimab across various clinical metrics.Immix Biopharma | Investor Presentation Deck | 56 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
30
Uses a before-and-after framing to illustrate market expansion potential.Immix Biopharma | Investor Presentation Deck | 56 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
31
The slide uses a structural layout to map platform capabilities to specific therapeutic products.Immix Biopharma | Investor Presentation Deck | 56 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
32
The slide uses a step-diagram to illustrate dose escalation.Immix Biopharma | Investor Presentation Deck | 56 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
33
Includes a process diagram illustrating the medical procedure and a list of key attributes.Immix Biopharma | Investor Presentation Deck | 56 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
34
Includes a comparative table of clinical outcomes (ORR, CR/sCR) for NXC-201 vs competitors.Immix Biopharma | Investor Presentation Deck | 56 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
35
The table highlights low incidence of severe adverse events and management protocols for NXC-201.Immix Biopharma | Investor Presentation Deck | 56 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
36
The slide highlights safety data (CRS and ICANS) and toxicity management interventions.Immix Biopharma | Investor Presentation Deck | 56 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
37
NXC-201 is highlighted with an orange border to emphasize its specific regimen.Immix Biopharma | Investor Presentation Deck | 56 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
38
The table compares clinical trial inclusion criteria across four different therapies for relapsed/refractory multiple myeloma.Immix Biopharma | Investor Presentation Deck | 56 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
39
Highlights NXC-201's competitive advantage regarding prior BCMA therapy exclusion.Immix Biopharma | Investor Presentation Deck | 56 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
40
The slide uses a numbered process flow layout.Immix Biopharma | Investor Presentation Deck | 56 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
41
The slide uses cross-trial comparison; disclaimer notes these are not head-to-head results.Immix Biopharma | Investor Presentation Deck | 56 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
42
Includes a scientific mechanism of action diagram at the bottom.Immix Biopharma | Investor Presentation Deck | 56 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
43
The slide uses a segmented horizontal axis to compare two distinct market segments by revenue.Immix Biopharma | Investor Presentation Deck | 56 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
44
The slide uses a hub-and-spoke style diagram to link the platform pillars to specific drug candidates.Immix Biopharma | Investor Presentation Deck | 56 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
45
Slide contains three distinct data charts and a summary of clinical trial plans.Immix Biopharma | Investor Presentation Deck | 56 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
46
Includes three distinct proof-of-concept data panels (penetration, biodistribution, apoptosis).Immix Biopharma | Investor Presentation Deck | 56 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
47
Includes waterfall chart and longitudinal line charts for patient cohorts.Immix Biopharma | Investor Presentation Deck | 56 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
48
The slide uses a bubble chart to show clinical trial outcomes and a table to detail efficacy/safety metrics across treatment lines.Immix Biopharma | Investor Presentation Deck | 56 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
49
The slide uses a combination of a conceptual chart and a data table to demonstrate efficacy and safety in heavily pre-treated patients.Immix Biopharma | Investor Presentation Deck | 56 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
50
Includes survival curves, bioluminescence imaging of mice, and tumor frequency metrics.Immix Biopharma | Investor Presentation Deck | 56 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
51
The slide uses a standard biological signaling pathway map to demonstrate the mechanism of action of the drug candidate.Immix Biopharma | Investor Presentation Deck | 56 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
52
Includes logos for BeiGene and Novartis.Immix Biopharma | Investor Presentation Deck | 56 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
53
Includes a comparison of iMX-111 size vs IgG antibody, GLUT1 expression across tissues, correlation with cancer stage, and a survival curve.Immix Biopharma | Investor Presentation Deck | 56 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
54
The slide uses a combination of mechanism diagrams, clinical trial bar charts, and preclinical mouse model data to validate the therapeutic approach.Immix Biopharma | Investor Presentation Deck | 56 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
55
The slide uses a bar chart comparison to establish a benchmark for clinical efficacy in the IBD market.Immix Biopharma | Investor Presentation Deck | 56 slides · Immix Biopharma
Pitch deck Investor relations 1 hit